2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa T, Weiss J, Schroeder M, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black J, Martínez-Ruiz C, Bakir M, Pich O, Watkins T, Lim E, Huebner A, Moore D, Godin-Heymann N, L’Hernault A, Bye H, Odell A, Kalavakur P, Gomes F, Patel A, Manzano E, Hiley C, Carey N, Riley J, Cook D, Hodgson D, Stetson D, Barrett J, Kortlever R, Evan G, Hackshaw A, Daber R, Shaw J, Aerts H, Licon A, Stahl J, Jamal-Hanjani M, Birkbak N, McGranahan N, Swanton C. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023, 616: 553-562. PMID: 37055640, PMCID: PMC7614605, DOI: 10.1038/s41586-023-05776-4.Peer-Reviewed Original ResearchConceptsCirculating tumor DNANon-small-cell lung cancerMetastatic disseminationClinical outcomesPlasma samplesEarly-stage non-small-cell lung cancerCirculating tumor DNA levelsCirculating tumor DNA detectionCytotoxic adjuvant therapyPreoperative ctDNA detectionResidual tumor cellsLongitudinal plasma samplesCancer cell fractionBiomarker of relapseProcess of metastatic disseminationAnalysis of plasma samplesClinical relapseDisease relapseAdjuvant therapyTumor DNAPreoperative plasmaRadiological surveillanceCtDNA detectionPatient cohortTumor cells
2021
YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells
Smith J, Rodríguez T, Mou H, Kwan S, Pratt H, Zhang X, Cao Y, Liang S, Ozata D, Yu T, Yin Q, Hazeltine M, Weng Z, Sontheimer E, Xue W. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells. Hepatology 2021, 73: 1011-1027. PMID: 32452550, PMCID: PMC8500588, DOI: 10.1002/hep.31389.Peer-Reviewed Original ResearchConceptsYes-associated protein 1Tumor cellsTumor regressionB-cateninStage IV hepatoblastomaResidual tumor cellsPediatric liver tumorsTherapeutic targetLong-term regressionTherapeutic differentiationHepatocyte-like morphologyFunctional hepatocyte-like cellsChildren's HbHB tumorsHepatocyte gene expressionHepatocyte-like cellsTranscription factor occupancyChemotherapeutic advancesTargeted therapyTumor landscapeLiver tumorsMurine modelHepatoblastomaTumorPromote cell death
2014
Significance of histology in determining management of lesions regrowing after radiosurgery
Nath SK, Sheridan AD, Rauch PJ, Yu JB, Minja FJ, Vortmeyer AO, Chiang VL. Significance of histology in determining management of lesions regrowing after radiosurgery. Journal Of Neuro-Oncology 2014, 117: 303-310. PMID: 24504499, DOI: 10.1007/s11060-014-1389-2.Peer-Reviewed Original ResearchConceptsBrain metastasesTumor cellsLocal controlSignificance of histologyWorse local controlResidual tumor cellsPost-treatment imagingManagement of lesionsOngoing patient managementInflammatory changesClinical outcomesResidual tumorSymptomatic enlargementAmbiguous etiologyHistologic findingsPatient outcomesPatient managementBrain specimensStereotactic radiosurgeryHistopathologic interpretationLesionsTissue specimensResectionPatientsMetastasis
2003
Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection
Jarnagin W, Zager J, Klimstra D, Delman K, Malhotra S, Ebright M, Little S, DeRubertis B, Stanziale S, Hezel M, Federoff H, Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Therapy 2003, 10: 215-223. PMID: 12637943, DOI: 10.1038/sj.cgt.7700558.Peer-Reviewed Original ResearchConceptsMicroscopic residual diseaseHerpes simplex virusParental tumorIL-12Hepatic tumorsResidual diseasePrimary treatmentTumor cellsTreatment of established tumorsOncolytic herpes simplex virusIL-12 in vitroImmune responseCD8(+) infiltrationLocal immune stimulationOncolytic HSV therapyRisk of cancer recurrenceReduce tumor recurrenceResidual tumor cellsTumor cell killingCD8(+) lymphocytesCellular immune dysfunctionGene transfer approachSignificant local immune responseIL-12 geneLocal immune response
2002
Increased Endocrine Cells in Treated Rectal Adenocarcinomas
Shia J, Tickoo S, Guillem J, Qin J, Nissan A, Hoos A, Stojadinovic A, Ruo L, Wong W, Paty P, Weiser M, Minsky B, Klimstra D. Increased Endocrine Cells in Treated Rectal Adenocarcinomas. The American Journal Of Surgical Pathology 2002, 26: 863-872. PMID: 12131153, DOI: 10.1097/00000478-200207000-00004.Peer-Reviewed Original ResearchConceptsChromogranin-positive cellsTreat rectal adenocarcinomaRectal adenocarcinomaChromogranin positivityNeoadjuvant therapyResected specimenTreatment responsePosttreatment specimensPretreatment biopsiesTumor cellsAbnormal p53 protein expressionTumors treated with radiotherapyCases of rectal adenocarcinomaEndocrine cellsDense chromatin patternPosttreatment resection specimensSubstantial treatment responsePretreatment biopsy specimensHematoxylin and eosin sectionsEndocrine differentiationResidual tumor cellsKi67 labeling indexP53 protein expressionDegree of treatment responseChromogranin staining
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply